MHRA approves zanidatamab for biliary tract cancer
The MHRA has approved zanidatamab (Ziihera) for adults with advanced biliary tract cancer that is HER2-high and has progressed after prior treatment; a single-arm study in 80 patients reported tumour shrinkage or no detectable disease in about 52% of the 62 HER2-high participants.
